Zealand Pharma, the biotech innovator transforming metabolic health, has announced the opening of a new research hub in Cambridge, Massachusetts. The facility, set to become the company’s primary US address, is slated to begin operations in September 2026.

 

“The Cambridge hub is a tangible commitment and an important addition to our research footprint – complementing the strong and active research already taking place in Denmark and marking another important step in our ambition to become a leader in obesity and metabolic health,” said Adam Steensberg, President and CEO of Zealand Pharma.

 

The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities, tapping into top-tier talent, cutting-edge technologies, and strategic partnerships in one of the world’s leading life science ecosystems. The site will accelerate AI-driven drug discovery, advanced automation, and next-generation molecule creation, moving scientific insights faster into innovative medicines.

 

Cambridge is home to more than 600 biotech and life sciences companies and leading academic institutions. Located at 35 CambridgePark Drive, the site—owned by Healthpeak (NYSE: DOC)—will position Zealand Pharma at the heart of the city’s innovation ecosystem. 

 

The hub will focus on AI, machine learning, and automation models to enhance drug design efficiency and expand the company’s pharmacological reach, including hybrid modalities like antibody-peptide conjugates (APCs) and siRNAs, as part of the Metabolic Frontier 2030 strategy. Zealand Pharma is actively hiring for the Cambridge site.

 

“Cambridge, Massachusetts is one of the world's great engines of biotech innovation, and we are excited to build our research hub where the metabolic expertise of Denmark and multi-modal platform capabilities from Cambridge can come together,” said Utpal Singh, Chief Scientific Officer. “This hub will deepen our discovery capabilities for medicine creation and help us move from idea to clinic faster.”